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Abstract: BACKGROUND Multiple breath washout (MBW) is increasingly used in the clinical assess-
ment of patients with cystic fibrosis (CF). Guidelines for MBW quality control (QC) were developed
primarily for retrospective assessment and central overreading. We assessed whether real-time QC of
MBW data during the measurement improves test acceptability in the clinical setting. METHODS We
implemented standardized real-time QC and reporting of MBW data at the time of the measurement
in the clinical pediatric lung function laboratory in Bern, Switzerland in children with CF aged 4-18
years. We assessed MBW test acceptability before (31 tests; 89 trials) and after (32 tests; 96 trials)
implementation of real-time QC and compared agreement between reviewers. Further, we assessed the
implementation of real-time QC at a secondary center in Zurich, Switzerland. RESULTS Before imple-
mentation of real-time QC in Bern, only 58% of clinical MBW tests were deemed acceptable following
retrospective QC by an experienced reviewer. After implementation of real-time QC, MBW test ac-
ceptability improved to 75% in Bern. In Zurich, after implementation of real-time QC, test acceptability
improved from 38% to 70%. Further, the agreement between MBW operators and an experienced reviewer
for test acceptability was 84% in Bern and 93% in Zurich. CONCLUSION Real-time QC of MBW data
at the time of measurement is feasible in the clinical setting and results in improved test acceptability.
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Abstract  1 
Background: Multiple breath washout (MBW) is increasingly used in the clinical assessment of 2 
patients with cystic fibrosis (CF). Guidelines for MBW quality control (QC) were developed 3 
primarily for retrospective assessment and central overreading. We assessed whether real-4 
time QC of MBW data during the measurement improves test acceptability in the clinical 5 
setting. 6 
 7 
Methods: We implemented standardized real-time QC and reporting of MBW data at the time 8 
of the measurement in the clinical pediatric lung function laboratory in Bern, Switzerland in 9 
children with CF aged 4-18 years. We assessed MBW test acceptability before (31 tests; 89 10 
trials) and after (32 tests; 96 trials) implementation of real-time QC and compared agreement 11 
between reviewers. Further, we assessed the implementation of real-time QC at a secondary 12 
center in Zurich, Switzerland. 13 
 14 
Results: Before implementation of real-time QC in Bern, only 58% of clinical MBW tests were 15 
deemed acceptable following retrospective QC by an experienced reviewer. After 16 
implementation of real-time QC, MBW test acceptability improved to 75% in Bern. In Zurich, 17 
after implementation of real-time QC, test acceptability improved from 38% to 70%. Further, 18 
the agreement between MBW operators and an experienced reviewer for test acceptability 19 
was 84% in Bern and 93% in Zurich. 20 
 21 
Conclusion: Real-time QC of MBW data at the time of measurement is feasible in the clinical 22 
setting and results in improved test acceptability. 23 
  24 
5 
 
1. Introduction 1 
The lung clearance index (LCI) derived from the multiple breath washout technique (MBW) is 2 
sensitive to detect early lung disease in patients with cystic fibrosis (CF) 1-4. With the 3 
availability of commercial MBW devices, LCI is increasingly being used as an outcome in 4 
routine clinical surveillance 5-10. While MBW testing requires minimal cooperation from the 5 
subject, an acceptable test requires relaxed tidal breathing and a leak-free system11, which 6 
can be challenging in young children and individuals with respiratory disease12. Besides, 7 
prospective quality control (QC)  of MBW measurements can be challenging in the busy clinical 8 
setting.  9 
Quality control guidelines for MBW focus primarily on retrospective analysis and central 10 
overreading of MBW measurements by experienced users for research studies and clinical 11 
trials 11,13-15. The 2013 European Respiratory Society (ERS) and American Thoracic Society (ATS) 12 
consensus statement for inert gas washout measurements proposed initial recommendations 13 
for testing procedure and technical acceptability criteria 11. Further to this, ATS published 14 
additional guidelines for the preschool age group 14. Jensen et al. proposed comprehensive 15 
guidelines for retrospective quality control of MBW measurements, which involved both 16 
qualitative and quantitative criteria for trial grading and acceptability13. These guidelines were 17 
further implemented in a standardized MBW training and quality control platform for central 18 
overreading in clinical trials 15. However, for LCI to be used as a clinical outcome, prospective 19 
reporting of acceptability and test results is required for clinical decision making.  20 
Therefore, we aimed to implement prospective, real-time quality control of MBW 21 
measurements in the clinical pediatric lung function laboratory in Bern, Switzerland. The first 22 
aim was to evaluate the acceptability of MBW measurements performed in routine outpatient 23 
clinics in children with CF before and after the implementation of real-time quality control. 24 
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The second aim was to assess the implementation of real-time quality control of MBW 1 
measurements in a pediatric lung function laboratory with less experience in MBW testing 2 
(Zurich, Switzerland). The third aim was to evaluate agreement in MBW test acceptability 3 
between the operator and a retrospective reviewer. 4 




2. Methods 1 
2.1 Development of MBW quality control criteria 2 
The quality control criteria used in this study were based on the ATS/ERS consensus statement 3 
guidelines, ATS pre-school MBW technical statement,  and the publications by Jensen et al 4 
and Saunders et al. 11,13-15. We used these guidelines to create a simplified matrix for 5 
qualitative assessment of Nitrogen (N2) MBW measurements performed in routine clinical 6 
testing that can be applied at the time of the measurement and did not require any further 7 
retrospective assessment.  8 
Our quality control criteria are presented in Table 1 and details of how our criteria differ from 9 
the ERS/ATS consensus statement are provided in Supplemental Table E1. Detailed 10 
instructions on how to apply the guidelines are presented in the online supplemental. An A 11 
grade represents a perfect trial with relaxed, regular tidal breathing throughout the 12 
measurement, a B grade represents a good quality trial with only minimal deviations, and a C 13 
grade represents an acceptable trial with moderate deviations but no highly abnormal breaths 14 
during the pre-phase or start of washout. A, B, and C grade trials are considered acceptable 15 
for outcome reporting. D grade represents trials with questionable quality due to variable 16 
breathing patterns, abnormal breaths, or evidence for hypo- or hyper-ventilation. D grade 17 
trials have no signs of leak and satisfy both the start and end of test criteria. However, D grade 18 
trials contain highly variable breathing patterns or abnormal breaths that might influence 19 
MBW results. While a clear consensus on how to handle trials with questionable breathing 20 
patterns has not been reached, we recommend rejection of D grade trials in our criteria. An F 21 
grade represents trials that need to be rejected due to not meeting the technical acceptability 22 
criteria for MBW: 1) Start of test criteria not met (last three breaths of pre-phase with 23 




consecutive tidal breaths with normalized end-tidal N2 concentration < 2.5%; 3) No evidence 1 
of leaks  (for detailed instruction see online supplemental). 2 
The overall test occasion is classified as acceptable when at least two trials are graded as 3 
acceptable (A, B, or C). We used the overall test repeatability criteria described in the 4 
consensus document (i.e. FRC variability within 25%)11. MBW outcomes from acceptable and 5 
repeatable test occasions are reported as the mean from all acceptable trials.  6 
2.2 MBW data collection and study population 7 
The N2MBW measurements were collected using the Exhalyzer D device (Eco Medics, 8 
Duernten, Switzerland) with Spiroware software (version 3.2.1) and were performed 9 
according to international guidelines in both centers 11. We approached all pediatric patients 10 
with CF attending their regular three monthly outpatient clinic visits aged 4 to 18 years. 11 
Approval was obtained from the local ethics committee in Bern. Patients and caregivers gave 12 
informed consent. 13 
2.3 Test acceptability before implementation of real-time MBW quality control in Bern 14 
Before implementation of real-time MBW quality control criteria into clinical routine in our 15 
centre, MBW operators were trained in data collection and general test acceptability. 16 
However, due to time restrictions, they were not required to perform a detailed assessment 17 
of test quality during the measurement. Operators occasionally excluded trials for outcome 18 
reporting in the software but did not routinely mark trial classification or test acceptability on 19 
the lung function reports. To assess the quality of these MBW measurements, 31 clinic visits 20 
from children with CF aged five to 18 years were evaluated. The visits were randomly selected 21 
by an independent person not involved in this study and only one visit per patient was 22 




reviewer who was involved in the development of the criteria and was blinded to any test 1 
comments by the MBW operator. The reviewer graded each trial individually and then 2 
assessed overall test acceptability.  3 
2.4 Test acceptability after implementation of real-time MBW quality control in Bern 4 
To implement real-time quality control of MBW measurements, operators in our center 5 
received instruction on how to perform quality control. A printed copy of the quality control 6 
criteria matrix was provided and operators were given a presentation on how to use the 7 
matrix, grade individual trials, determine test acceptability and repeatability, and report 8 
outcomes (detailed information provided in online supplement). All MBW operators were 9 
required to perform real-time quality control on all MBW measurements. The operators 10 
reported a grade for each trial and provided a standardized comment regarding the 11 
acceptability of the test occasion in the clinical report (example provided in the online 12 
supplement).  13 
To assess the quality of MBW measurements after implementation of real-time quality control 14 
in routine clinical testing, 32 clinic visits from the same population of children with CF were 15 
evaluated. The visits were randomly selected by an independent person not involved in this 16 
study and only one visit per child was assessed. The experienced reviewer performed 17 
retrospective quality control of these measurements while being blinded to the real-time 18 
quality control assessment of the operator.  19 
2.5 Assessment of real-time MBW quality control in a secondary centre in Zurich 20 
To validate our findings, we implemented real-time MBW quality control in a centre (Zurich, 21 
Switzerland) with less experience in MBW methodology. We first assessed MBW 22 




attending their routine care in Zurich, Switzerland. The MBW operators were then instructed 1 
on how to use the quality control matrix and given access to the supplementary teaching 2 
material (see online supplemental). Mandatory real-time MBW quality control and reporting 3 
of test acceptability were implemented for all measurements. We then retrospectively 4 
assessed test acceptability and agreement between the operator and reviewer in a random 5 
subset of 30 MBW measurements. 6 
2.6 Outcomes before and after real-time quality control  7 
To determine whether performing real-time quality control influenced outcomes, we 8 
compared mean outcomes (LCI and FRC) and variability (coefficient of variation; (CV)) for each 9 
test occasion before and after quality control. Before real-time quality control was 10 
implemented, we examined the differences in the outcomes printed on the clinical report to 11 
outcomes from trials deemed acceptable by the reviewer. After implementing real-time 12 
quality control, we compared differences in the outcomes reported prospectively by the 13 
operator vs retrospectively assessed by the reviewer.  14 
We also performed a sensitivity analysis to examine the impact of accepting or rejecting D 15 
grade trials on outcome calculation and overall test acceptability.  16 
2.7 Data analysis 17 
For this study, we examined MBW test acceptability before and after implementation of real-18 
time quality control in the clinical setting. Before the implementation of real-time quality 19 
control, we compared test acceptability reported in the clinical reports generated by MBW 20 
operators to those reported following retrospective quality control by the experienced 21 
reviewer (BF). While trial classification was not documented on the printed report before 22 




spiroware software. After the implementation of real-time quality control, we compared test 1 
acceptability and trial acceptability reported at the time of the measurement by MBW 2 
operators to those reported following retrospective quality control by the experienced 3 
reviewer (BF).  As a secondary outcome, we assessed the agreement in test acceptability and 4 
trial grading between the MBW operator and an experienced reviewer. Agreement was 5 
assessed using kappa statistics. We also compared MBW outcomes from accepted test 6 
occasions (mean and within-test coefficient of variation for FRC and LCI) reported by the 7 
operator and reviewer using unpaired t-tests. All statistical analysis was performed using Stata 8 
16.0 (StataCorp 2019)16. 9 




3. Results 1 
3.1 Study population 2 
The demographic characteristics of study participants from both centers are summarized in 3 
Table 2. The population in Zurich was on average younger, however, the age range of patients 4 
was similar between both centers. Anthropometric characteristics (height, weight, BMI, and 5 
age) and MBW outcomes (LCI and FRC) were well matched between the two study 6 
populations. 7 
3.2 MBW test and trial acceptability before implementing real-time quality control 8 
MBW test acceptability results are summarized in Table 3. In Bern, before implementing real-9 
time quality control, 89 MBW trials from 31 test occasions were evaluated. After retrospective 10 
analysis of quality control by the reviewer, 58% of test occasions were deemed acceptable. In 11 
terms of MBW trials, 51 (58%) were accepted, and 38 (42%) were rejected following 12 
retrospective quality control by the reviewer. The reasons for trial rejection (details provided 13 
in Table 4) included F grade trials whereby the technical acceptability criteria were not met 14 
and D grade trials with irregular breathing patterns. 15 
In Zurich, before implementing real-time quality control, 97 MBW trials from 34 test occasions 16 
were evaluated. After retrospective quality control by the reviewer, only 38% of the test 17 
occasions were deemed acceptable. In terms of MBW trials, 44 (45%) were accepted and 53 18 
(55%) were rejected following retrospective quality control by the reviewer. The reasons for 19 
trial exclusion (details provided in Table 4) were similar to Bern.  20 
3.3 MBW test and trial acceptability after implementing real-time quality control 21 
Test acceptability after implementing real-time MBW quality control is summarized in Table 22 




from 58% (18/31) to 75% (24/32) and trial acceptability improved from 58% (51/89) to 69% 1 
(66/96) (Table 5).  In Zurich, 91 trials from 30 MBW test occasions were evaluated after 2 
implementing real-time quality control. Test acceptability improved from 38% (13/34) to 70% 3 
(21/30), trial acceptability improved from 45% (44/97) to 67% (61/91) (Table 5).  4 
3.4 Agreement between MBW operator and reviewer after implementing real-time quality 5 
control 6 
After implementing real-time quality control, the agreement between operator and reviewer 7 
was high in both centers. For test acceptability agreement was 84% (ĸ = 0.5, p < 0.001) in Bern 8 
and 93% (ĸ = 0.8, p =0.001) in Zurich. In Bern, four test occasions were rejected by the reviewer 9 
but not by the operator. The remaining four test occasions rejected by the reviewer were also 10 
rejected by the operator. In Zurich, only one test occasion was rejected by the reviewer but 11 
not by the operator, the remaining eight test occasions rejected by the reviewer were also 12 
rejected by the operator. 13 
For trial grading, agreement was 68% (ĸ = 0.6, p < 0.001) in Bern and 73% (ĸ = 0.6, p < 0.001)  14 
in Zurich. When pooling the analysis to the comparison of acceptable (A-C grade), 15 
questionable (D grade) and rejected (F grade) trials, agreement in Bern was 88% (ĸ = 0.7, p 16 
<0.001) and in Zurich 86% (ĸ = 0.7, p <0.001) (Figure 1a and 1b). In Bern, operators identified 17 
all F grade trials, except for one which was given a D grade. In Zurich, 15/19 (80%) of the F 18 
grade trials were correctly identified by the operator, whereas two of the F grade trials were 19 
classified as D grade and two were classified as A-C grade by the operator. F grade trials 20 
consisted mostly of leaks, and the only trials in which the end of test criteria was not met were 21 
trials that were prematurely terminated by the operator. All the trials evaluated satisfied the 22 
start of test criteria, which meant that operators were consistently waiting enough time 23 




3.5 MBW outcomes before and after quality control 1 
We determined whether performing quality control significantly influenced MBW results. We 2 
found no differences in LCI or FRC mean values or variability reported by the MBW operator 3 
at the time of the measurement compared with the reviewer; for both periods, before the 4 
implementation of real-time quality control and after implementation (Supplemental Table E2 5 
and E3). However, for individuals, performing quality control can have a minor impact on the 6 
outcomes (maximum change is +/- 0.5 LCI units), as shown in the Bland-Altman-Plot in the 7 
online supplemental Figure E1 and E2. 8 
We performed a sensitivity analysis to determine the impact of accepting or rejecting 9 
questionable D grade trials. Accepting D grade trials increased overall test acceptability from 10 
75% to 84% in Bern and from 70% to 90% in Zurich, and did not lead to significant differences 11 
in LCI and FRC (Supplemental Table E4).  12 
 13 




4. Discussion 1 
We assessed the quality of MBW measurements collected in clinical routine before and after 2 
implementing mandatory real-time quality control in two centers. We provided the MBW 3 
operators with a simplified quality control matrix according to current guidelines and assessed 4 
whether real-time quality control of MBW data during the measurement improves test 5 
acceptability in routine clinical testing. Following implementation of real-time quality control, 6 
acceptability of MBW measurements improved from 58% to 75% in Bern and from 38% to 70% 7 
in the validation center Zurich and resulted in excellent agreement between the operator and 8 
reviewer. 9 
Implementing mandatory real-time quality control improved overall test acceptability and the 10 
ability of MBW operators to recognize and perform good quality MBW measurements in 11 
routine clinical testing. Before implementation of real-time quality control criteria, operators 12 
reported outcomes to the clinicians with trials that should have been rejected according to 13 
current quality control guidelines 11,13-15. After implementing mandatory real-time quality 14 
control and providing the simplified guidelines in Bern, operators were able to correctly 15 
identify acceptable, questionable, and technically not acceptable trials with excellent 16 
agreement to an experienced reviewer. These findings were validated in a center with less 17 
experience in MBW measurements (Zurich) with similar agreement. We could show that 18 
performing real-time quality control in the clinical setting is feasible and that the improved 19 
compliance of our operators with the quality control guidelines resulted in higher test 20 
acceptability rates.  21 
Our quality control guidelines are a simplified version of the current MBW consensus 22 
guidelines, preschool technical standards, and quality control guidelines by Jensen et al. and 23 




there has been a focus on the need for detailed retrospective quality control and central over-1 
reading by highly experienced MBW researchers. While central over-reading is a suitable 2 
approach for large, multi-centre research studies15,17, MBW testing in routine outpatient 3 
clinics requires immediate reporting of outcomes. Therefore, real-time quality control by the 4 
operator is the only way to ensure that good quality MBW outcomes are used for clinical 5 
interpretation. Our quality control criteria (Table 1) provide simplified guidelines for MBW trial 6 
grading, trial acceptability, and test acceptability. They can be applied at the time of the 7 
measurement to allow immediate reporting of MBW data in clinics. We did not specifically 8 
assess if extra time was needed for reporting. However, MBW operators were encouraged to 9 
perform quality control during the waiting time between trials. The time-slots for MBW testing 10 
remained the same after implementing mandatory quality control, which indicates that not 11 
much extra time was necessary. To maintain high-quality MBW data in the clinical setting, we 12 
suggest that centres implement regular training sessions with operators, provide updates of 13 
recent literature in the field, and perform regular over-reading of random subsets of MBW 14 
measurements to provide feedback to the operators.  15 
We found that systematic quality control of MBW measurements by an experienced reviewer 16 
did not lead to differences in mean LCI or FRC values compared with values reported without 17 
quality control. These findings are similar to those reported by Jensen et al., who found no 18 
differences in mean LCI values following qualitative and quantitative review13. However, while 19 
both studies reported no significant differences in outcomes on a population level 18, reporting 20 
outcomes from technically not acceptable MBW trials can impact the outcomes of a test 21 
occasion on an individual level as we could show by comparing individual outcomes before 22 
and after quality control in supplemental Figures E1 and E2. In the clinical setting, longitudinal 23 




decisions. Therefore, it is essential to ensure that only data from good quality MBW trials are 1 
reported.  2 
In the clinical setting, trials that satisfy the technical acceptability criteria but have highly 3 
irregular breathing patterns (D grade trials) are a frequent challenge. There are limited data 4 
on the impact of non-tidal breaths and different degrees of tidal breathing variability on 5 
outcomes. However, the general consensus is that these questionable D grade trials should 6 
be rejected to avoid the potential impact on results and test variability 11,13-15. We performed 7 
a sensitivity analysis and found that accepting D grade trials increased overall test 8 
acceptability without significantly influencing results. However, we found in general little 9 
differences in outcomes before and after the implementation of quality control. Further 10 
research will help to determine the impact of breathing pattern irregularities on MBW 11 
outcomes to inform quality control inclusion and exclusion criteria. However, to ensure 12 
reliability of MBW results for clinical reporting, we support the current recommendation to 13 
not accept questionable trials with irregular breathing patterns and perform strict quality 14 
control. 15 
There are some limitations to our quality control criteria. Trial grading is based on qualitative 16 
criteria for breathing pattern that are inherently subjective. Users need to have familiarity 17 
with the MBW test to differentiate between minimally and moderately variable breathing 18 
pattern. However, many of these subjective criteria will only influence whether a trial is 19 
graded as either A, B or C, all of which are technically acceptable trials. Our criteria could have 20 
been simplified further to only include acceptable, questionable, or rejected trial grading, 21 
however, MBW operators stated that it was beneficial to be able to recognize what constitutes 22 
a technically perfect trial and understand which deviations can still be accepted. Further, our 23 




performed using Eco Medics equipment and Spiroware 3.2.1 software whereby flow-volume 1 
loops, nitrogen, oxygen, and carbon dioxide signals are visible during and after the 2 
measurement. It is unclear how easily these criteria can be applied to data collected in other 3 
devices, software, and alternative tracer gases. 4 
 5 
Conclusion 6 
Real-time quality control of MBW data at the time of the measurement is feasible in the 7 
clinical setting and results in improved test acceptability with excellent agreement between 8 
MBW operators and experienced reviewers. Our quality control criteria provide simplified 9 
guidelines for MBW trial grading, trial acceptability, test acceptability, and outcome reporting 10 
that can be applied in centers with limited experience in MBW methodology. Performing 11 
quality control at the time of the measurement ensures that only outcomes from good quality 12 
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Table 1: Quality control criteria 
A (perfect) Pre-phase Regular tidal breathing: relaxed, regular, and appropriate for size 
 Start of washout Regular tidal breathing: relaxed, regular, and appropriate for size 
 Rest of washout Regular tidal breathing: relaxed, regular, and appropriate for size 
 EELV Stable: no drift or step change 
B (good) Pre-phase Regular tidal breathing: relaxed, regular, and mostly appropriate for size 
 Start of washout Regular tidal breathing: relaxed, regular, and mostly appropriate for size 
 Rest of washout Minimally variable breathing: flow minimally variable, irregular (small swallow/hesitation), VT slightly outside 
target range 
 EELV Minimal to moderate drift; no step change 
C (acceptable) Pre-phase Minimally variable breathing: flow minimally variable, irregular (small swallow/hesitation), VT outside target 
range 
 Start of washout Minimally variable breathing: flow minimally variable, irregular (small swallow/hesitation), VT outside target 
range 
 Rest of washout Moderately variable breathing: flow moderately variable, abnormal breath (sigh, cough, breath-hold) with no 
release of trapped gas, VT outside target range  
 EELV Minimal to moderate drift; step change in rest of washout with no shift in N2 signal 
D 
(questionable) 
Pre-phase Moderately variable breathing: flow moderately variable, abnormal breath (sigh, cough, breath-hold), VT outside 
target range 
 Start of washout  Moderately variable breathing: flow moderately variable, abnormal breath (sigh, cough, breath-hold), VT outside 
target range 
 Rest of washout  Highly variable breathing: flow highly variable, forced expiration, abnormal breath (sigh, cough, breath-hold) 
with release of trapped gas, evidence for hypo/hyperventilation (CO2 outside 4-6% range) 
 EELV  Step change in rest of washout resulting in shift in N2 signal 
F (reject) Start of test criteria (last three breaths of pre-phase N2 concentration ≥ 77%) not met  
End of test criteria (three consecutive tidal breaths with normalized N2 concentration < 2.5%) not met  
Leak during washout 
Overall test 
acceptability 
Minimum two acceptable trials 
A, B, C trials Accept (if FRC variability within 25%) 
 D trials Review carefully, recommended to reject 
 F trials Reject 
Definition of abbreviations: EELV = end expiratory lung volume; LCI = lung clearance index; FRC = functional residual capacity; VT = tidal volume; 
CO2 = end tidal concentration of carbon dioxide; N2 = end tidal concentration of nitrogen. Target range for VT defined as 10-15ml/kg (represents 
green line in flow-volume figure). For our quality control criteria we define the pre-phase as the three breaths preceding the start of the 
washout. The start of the washout is defined as the first breaths of the washout, and the rest of the washout includes all the remaining breaths 
of the washout until the end of test criteria is reached (including first three breaths below 2.5% normalized end tidal nitrogen concentration).
  
Table 2: Patient demographics 
 Bern Zurich 
 Before real-time QC After real-time QC Before real-time QC After real-time QC 
Patients (n) 31 32 34 30 
Female: n (%) 16 (52) 17 (53) 13 (38) 9 (30) 
Age (years) 12.9 (5.2; 18.1) 13.4 (5.6; 18.1) 10 (4.0; 18) 11 (4.2; 18.2) 
Weight (kg) 42.4 (19.4; 68) 44.2 (19.9; 74.2) 32.2 ( 15; 68) 40 (16; 96) 
Weight z-score -0.3 (-1.8; 1.6) -0.4 (-3.3; 1.7) -0.2 (-2.2; 2.0) 0.09 (-1.8; 2.8) 
Height (cm) 150.2 (110.8; 180) 150.7 (117.4; 183.5) 133.5 (99; 172) 141.8 (99; 177) 
Height z-score -0.1 (-3.4; 1.4) -0.6 (-4.2; 3.3) -0.4 (-2.4; 1.7) -0.07 (-1.3; 1.4) 
BMI (m/kg2) 18.2 (14; 25.3) 18.9 (14.4 ; 24.8) 17.2 (13.7; 26) 18.2 (13.7; 28) 
BMI z-score -0.2 (-1.6; 1.7) -0.01 (-1.61; 1.41) 0.03 (-2.1; 2.3) 0.13 (-2.7; 2.8) 
LCI 2.5% 11.0 (7.3; 19) 10.8 (7; 17.3) 11.3 (6.5; 19.4) 9.7 (6;  15.2) 
FRC (L) 1.9 (0.9; 3.8) 1.9 (0.8; 3.7) 1.6 (0.7; 3.2) 2.0 (0.6; 3.8)  
Data are presented as mean (range) or n (%). Definition of abbreviations: BMI = Body mass index, LCI: Lung clearance 
index, FRC: Function residual capacity, QC: Quality control. Subjects were all children with CF attending routine care at 
the CF outpatient clinics in Bern and Zurich and randomly selected for this study. Results presented for LCI and FRC refer 
to the test occasions accepted by the reviewer.  
Table 3: MBW trial and test acceptability 









Test occasions (n) 31 32 34 30 
Test acceptability  
(at least two acceptable trials) 
18 (58) 24 (75) 13 (38) 21 (70) 
Tests with 2 acceptable trials 11(61) 11(46) 2 (15) 9 (43) 
Tests with 3 or more acceptable trials 7 (39) 13 (54) 11(85) 12 (57) 
Abbreviations: QC: quality control. Total Number of test occasions evaluated. For a valid test occasion, a minimum of 2 
acceptable trials is required. Percentages of accepted tests refer to the total number of tests collected. Percentages of tests 





Table 4: Reasons for trial exclusion before implementing real-time quality control 
 Bern Zurich 
Before real-time QC 
Trials evaluated 89 97 
Trials rejected 38 (42) 53 (55) 
F grade trials 16 (42) 36 (68) 
End of test criteria not met 7 (44) 4 (11) 
Leak during washout 6 (37) 29 (81) 
Start of test criteria not met 3 (19) 3 (8) 
D grade trials  22 (58) 17 (32) 
Abbreviations: QC: quality control. Number of trials evaluated before real-time quality control was implemented 
with reasons provided for trial exclusion. Percentage of trials with D and F grade refers to the total number of 
trials rejected. F grade trials were excluded as not meeting technical acceptability criteria, percentage given refers 
to the total number of F grade trials. D grade trials were of questionable quality and therefore excluded for test 
interpretation.  
 
Table 5: Reasons for trial exclusion after implementing real-time quality control  
 Operator Reviewer 
Bern 
Trials evaluated 96 96 
Trials rejected 27 (28) 30 (31) 
F grade trials 18 (67) 18 (60) 
End of test criteria not met 10 (56) 10 (56) 
Leak during washout 8 (44) 8 (44) 
Start of test criteria not met 0 (0) 0 (0) 
D grade trials 9 (33) 12 (40) 
Zurich   
Trials evaluated 91 91 
Trials rejected 32 (35) 30 (33) 
F grade trials 18 (56) 19 (63) 
End of test criteria not met 4 (22) 5 (26) 
Leak during washout 14 (78) 14 (74) 
Start of test criteria not met 0 (0) 0 (0) 
D grade trials 14 (44) 11 (37) 
Abbreviations: QC: quality control. Number of trials evaluated after real-time quality control was 
implemented with reasons for trial exclusion provided for the operator and the reviewer in Bern and 
Zurich, respectively. Percentage of trials with D and F grade refers to the total number of trials 
rejected. F grade trials were excluded as not meeting technical acceptability criteria, percentage given 
refers to the total number of F grade trials. D grade trials were of questionable quality and therefore 






Figure 1a: Agreement in trial grading between operator and reviewer after implementing 
quality control guidelines in Bern. A total number of 96 trials were evaluated in Bern; 
Agreement for trial grading into acceptable, questionable, and rejected was 88% (kappa 0.7, 
p< 0.001). A-C grade trials reflect acceptable trials, D grade trials are questionable quality, and 
F Grade are technically not acceptable. 
 
 
Figure 2b: Agreement in trial grading between operator and reviewer after implementing 
quality control guidelines in Zurich. A total number of 91 trials were evaluated in Zurich; 
Agreement for trial grading into acceptable, questionable, and rejected was 86% (kappa 0.7, 
p<0.001). A-C grade trials reflect acceptable trials, D grade trials are questionable quality, and 
F Grade are technically not acceptable. 
 
Online supplemental material 
  
Real-time quality control guidelines 
 
We propose to assess N2MBW measurements systematically at three different phases of the measurement. Initially, we examine the ‘pre-phase’, 
which includes all the breaths prior to the washout and provides the baseline for the measurement. We define the pre-phase as the three breaths 
immediately preceding the start of the washout. Second, we examine the ‘start of the washout’, which we define as the first three breaths of the 
washout. Finally, we examine the ‘rest of the washout’, which includes all the remaining breaths of the washout until the end of test criteria is 
reached (including the first three breaths below 2.5% normalized end tidal nitrogen concentration).  
The pre-phase and start of the washout are important for the calculation of outcomes FRC and LCI. The FRC is calculated as the net volume of 
exhaled N2 divided by the difference in end tidal N2 concentration from the start (CetN2start) to the end of the washout (CetN2end). The LCI is 
calculated as the cumulative expired volume (CEV) divided by FRC (Equation 1). 
    
The pre-phase is used to calculate the CetN2start and is therefore important for the calculation of FRC. The net volume of exhaled N2 is calculated 
based on the integration of N2 concentration with respect to flow. As the first three breaths of the washout have the largest concentrations of 
exhaled N2 they have the biggest influence on the net volume of exhaled N2. Therefore, the start of the washout is important for the calculation of 
both FRC and LCI. Alterations from regular tidal breathing during the pre-phase and start of washout can have a large influence on outcomes and 
are dealt with more strictly in our criteria.   
Supplemental Table E1: Definition of how our quality control criteria differ from the ATS/ERS consensus statement criteria 
 ATS/ERS Consensus statement Additional (+) / modified (*) criteria in our matrix 
Evidence of leak A sudden spike in N2-concentration during inspiration; premature rise 
in N2 signal in early expirogram where N2 should be zero; Decrease in 
airway dead space volume; A sudden step change in volume trace or 
step-up in N2- concentration plotted vs. lung turnover (TO) 
+ Loss of decay or prolonged plateau in end-tidal concentration of N2;  
+ Concentration of N2 does not return to zero on inspiration 
End of test criteria Three consecutive breaths where the normalized end-tidal 
concentration of N2 fell  below 2.5% 
+ All  three breaths should be tidal breaths 
Start of test criteria Sufficient interval between runs when using resident inert gases to 
allow inert gas concentration to return to baseline values 
+ End-tidal concentration of N2 for last three breaths of pre-phase ≥77% 
Pre-phase (last three breaths of pre-phase) 
Tidal Volume (VT) Stable VT and EELV over the preceding 30 s prior to start washout; No 
small volume breath immediately prior to start of washout 
* Tidal volume stable and relaxed; no sigh, cough, breath-hold, or small 
breath; small swallow/hesitation acceptable 
End expiratory lung 
volume (EELV) 
Deviation in EELV at start of washout within 10% of mean VT of 5 
breaths immediately preceding the start of washout 
* No step change in EELV; stable minimal to moderate drift is acceptable 
Start of washout (first three breaths of washout): 
Tidal Volume (VT) Tidal volume stable and relaxed; regular breathing pattern * Tidal volume stable and relaxed; no sigh, cough, breath-hold, or small 
breath; small swallow/hesitation acceptable 
End expiratory lung 
volume (EELV) 
Stable volume drift is acceptable; A sudden step change in volume 
time trace is acceptable provided leak was ruled out 
* No step change in EELV; stable minimal to moderate drift is acceptable 
Rest of washout: 
Tidal Volume (VT) Tidal volume stable and relaxed; regular breathing pattern * Tidal volume can be moderately variable; Abnormal breaths (sigh, cough, 
breath-hold) with no leak or release of trapped gas are acceptable 
End expiratory lung 
volume (EELV) 
Stable volume drift is acceptable; EELV is stable during washout; A 
sudden step change in volume time trace is acceptable provided no 
leak 
* Step change with no shift in N2 signal acceptable 
Flow No coughing * No evidence of forced exhalation, cough with flow exceeding 1000ml/s, 
highly erratic flow 
Trapped Gas 
Release 
No evidence of significant trapped gas release with larger breaths. + No evidence of significant trapped gas release (increased end tidal N2 
concentration) with sigh or large breath 
Respiratory rate  + No evidence of hyper or hypoventilation 
Repeatability FRC within 25% of the median FRC of all technically acceptable trials  
 
 
Definition of our quality control criteria (for acceptable trials) and how it differs from the ATS/ERS consensus statement criteria The symbol ‘+’ indicates 
additive criteria further to the ATS/ERS consensus statement criteria. The symbol ‘*’ indicates modified criteria to the ATS/ERS consensus statement criteria. 
Definition of abbreviations: EELV = end expiratory lung volume; LCI = lung clearance index; FRC = functional residual capacity; VT = tidal volume; CO2 = end tidal 
concentration of carbon dioxide; N2 = end tidal concentration of nitrogen; TO = lung turnover. Target range for VT defined as 10-15ml/kg (represents green line 
in flow-volume figure). For our quality control criteria we define the pre-phase as the three breaths preceding the start of the washout. The start of the 
washout is defined as the first breaths of the washout, and the rest of the washout includes all the remaining breaths of the washout until the end of test 
criteria is reached (including first three breaths below 2.5% normalized end tidal nitrogen concentration). 
 
  
Supplemental Table E2: Outcomes before and after implementing real-time quality control (Bern) 
Before real-time QC Clinical Report Reviewer p-value 
LCI 2.5%  11.6 (3.7) 11.0 (3.4) 0.5 
FRC (L)  1.9 (0.7) 1.9 (0.8) 1.0 
LCI 2.5% CV  5.2 (3.2) 5.5 (3.2) 0.7 
FRC (L) CV  5.3 (3.7) 4.5 (3.6) 0.5 
After real-time QC Operator Reviewer p-value 
LCI 2.5%  11.3 (2.9) 10.8 (2.6) 0.6 
FRC (L)  1.8 (0.7) 1.9 (0.7) 0.8 
LCI 2.5% CV  4.5 (3.1) 4.8 (3.3) 0.7 
FRC (L) CV  4.2 (3.3) 4.5 (3.9) 0.7 
Data are presented as mean (standard deviation) or n (%). Definition of abbreviations: QC: quality control, LCI: lung 
clearance index, FRC: Functional residual capacity, CV: coefficient of variation (%). The ‘before real-time QC’ 
comparison examined differences in the outcomes printed on the clinical report vs the outcomes from the trials 
deemed acceptable by the reviewer.  The ‘after real-time QC’ comparison examined differences in the outcomes 




Supplemental Table E3: Outcomes before and after implementing real-time quality control (Zurich) 
 
Before real-time QC Clinical Report Reviewer p-value 
LCI 2.5%  11.3 (3.2) 11.3 (2.9) 0.9 
FRC (L)  1.5 (0.7) 1.6 (0.6) 0.6 
LCI 2.5% CV  6.9 (4.3) 5.7 (3.2) 0.4 
FRC (L) CV  7.0 (6.8) 5.1 (3.4) 0.3 
After real-time QC Operator Reviewer p-value 
LCI 2.5%  9.8 (2.7) 9.7 (2.6) 0.8 
FRC (L)  2.0 (0.8) 2.0 (0.8) 1.0 
LCI 2.5% CV  5.2 (3.1) 5.3 (2.9) 0.9 
FRC (L) CV  4.8 (2.2) 4.6 (2.0) 0.8 
Data are presented as mean (standard deviation) or n (%). Definition of abbreviations: QC: quality control, LCI: lung 
clearance index, FRC: Functional residual capacity, CV: coefficient of variation (%). The ‘before real-time QC’ 
comparison examined differences in the outcomes printed on the clinical report vs the outcomes from the trials 
deemed acceptable by the reviewer.  The ‘after real-time QC’ comparison examined differences in the outcomes 
reported prospectively by the operator vs retrospectively by the reviewer. 
 
  
Supplemental Table E4: Impact on outcomes when including D grade trials  
 Excluding D grade trials Including D grade trials p-value 
LCI 2.5%  10.3 (0.4) 10.2 (0.4) 0.9 
FRC (L)  1.9 (0.11) 1.8 (0.1) 0.5 
LCI 2.5% CV  5.0 (0.46) 5.0 (0.41) 0.9 
FRC (L) CV  4.5 (0.46) 4.8 (0.45) 0.7 
Data are presented as mean (standard deviation). Definition of abbreviations: LCI = lung clearance index, FRC = Functional 
residual capacity, CV: coefficient of variation (%). Results are pooled for both centers. Results presented compare the 
mean outcomes from all acceptable test occasions including D grade trials (n = 54) to acceptable test occasions whereby D 







Supplemental Figure E1: Impact of performing quality control on individual test occasions for LCI  

















Figure E1: Bland Altman Plot for the difference in LCI before and after performing quality control. We compared the outcomes reported to the 
clinicians at the time of the measurement before real-time quality control was introduced to the outcomes when test occasions were assessed by 
the reviewer. While we found no differences in LCI before and after quality control on a population level, the impact of performing quality control 
for an individual can have a minor impact (+/-0.5 LCI points). Dark grey dots represent mean LCI for each individual, the solid line the mean 
difference, and the dotted lines the 95% limits of agreement. 
 
  
Supplemental Figure E2: Impact of performing quality control on individual test occasions for FRC 



















Figure E2: Bland Altman Plot for the difference in FRC before and after performing quality control. We compared the outcomes reported to the 
clinicians at the time of the measurement before real-time quality control was introduced to the outcomes when test occasions were assessed by 
the reviewer. While we found no differences in FRC before and after quality control on a population level, the impact of performing quality 
control for an individual can have a minor impact (+/-0.1 Litre FRC). Dark grey dots represent mean FRC for each individual, the solid line the mean 
difference, and the dotted lines the 95% limits of agreement. 
 
